Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Pfizer earnings, NAD decision, DXM bill, FDA warning, regulatory agenda

This article was originally published in The Tan Sheet

Executive Summary

Pfizer’s OTC pain sales drop; NAD Procera AVH claims to FTC; House introduces DXM bill; FDA warns medical food firm; Regulatory Agenda pushes back OTC actions; meetings address terrorism-related food adulteration; and more news In Brief.

You may also be interested in...



FSA/HSA Coverage Tops CHPA 2014 Legislative Goals

The Consumer Healthcare Products Association’s No. 1 legislative priority in 2014 is restoring OTC coverage by flexible spending and health savings accounts, followed by a “close No. 2” goal of establishing an age requirement to buy DXM products. Other goals include protecting access to PSE products and blocking take-back programs.

FDA Says Antiseptics Need Testing Or Face Reformulation, Relabeling

FDA proposes to amend the OTC antiseptic drug product monograph to require more detailed safety and efficacy tests, pointing to mounting data that shows antibacterial wash products could pose health risks and contribute to increase antibacterial resistance.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel